Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Esophageal cancer
Stage/Subtype:  stage IV esophageal cancer
Trial Type:  Treatment
Results 1-25 of 36 for your search:
Start Over
Radiation Therapy with Docetaxel and Fluorouracil in Treating Patients with Esophageal Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2009-0847, NCI-2011-02030, NCT01102088
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLJM716X2103, NCI-2013-01355, NCT01822613
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, 348360, P131392, NCT02054104
Pembrolizumab and Combination Chemotherapy in Treating Patients with Advanced Colorectal, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
Irinotecan Hydrochloride and Panitumumab as Second-Line Therapy in Treating Patients With Locally Recurrent or Metastatic Esophageal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: 07-161, NCI-2011-02478, NCT00836277
Tumor Infiltrating Lymphocytes and Aldesleukin after Chemotherapy in Treating Patients with Metastatic Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0166, NCI-2013-01461, 100166, P09567, NCT01174121
Afatinib Dimaleate and Trastuzumab in Treating Patients with Refractory Metastatic Esophagus or Stomach Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-166, NCI-2012-00414, NCT01522768
Plicamycin in Treating Patients with Malignancies Involving the Lungs, Esophagus, or Pleura That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-C-0151, NCI-2013-01534, 120151, 319435, 348342, P12961, NCT01624090
Biomarkers in Predicting Response to Docetaxel, Cisplatin, and Fluorouracil in Patients With Metastatic Esophagus, Gastroesophageal Junction, or Stomach Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: J1248/ NA_00073720, NCI-2013-00058, J1248, NCT01715233
Combination Chemotherapy in Treating Patients with Advanced Stomach, Gastroesophageal, or Esophageal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201309035, NCI-2013-01783, NCT01928290
Nintedanib in Treating Patients with Advanced Esophageal, Gastroesophageal Junction, or Stomach Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-094, NCI-2014-01964, NCT02234596
Afatinib and Paclitaxel in Treating Patients with HER2-Positive Recurrent Advanced Gastric, Gastroesophageal Junction, or Esophageal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAM5905, NCI-2015-00758, 1200.203, NCI-2014-02350, NCT02274012
Personalized Therapy Using Genetic Markers in Treating Patients with Esophagogastric Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201412051, NCI-2014-02550, NCT02296671
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Autologous Cytotoxic T Lymphocytes in Treating Patients With Advanced HER2- Positive Malignancy
Phase: Phase I
Type: Treatment
Age: 3 and over
Trial IDs: H-24486, NCI-2012-00777, NCT00889954
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-078, NCI-2011-02511, CDR0000689900, NCT01249443
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
Vaccine Therapy in Treating Patients with Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor 2 Positive Cancers
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00034612, NCI-2013-00525, NCT01526473
Start Over